Biomarker ID | 934 |
PMID | 22640805 |
Year | 2012 |
Biomarker | NACA + CCNB1 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (CCNB1): T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway |
Experiment | BPC VS BP |
Type of Biomarker | Diagnostic |
Cohort | Confirmation Set: 37 PCas and 36 unmatched benign prostates containing PCa (BPCs) and were contrasted with 28 benign prostates (BPs) from patients free of PCa. Validation Set: independent set of 51 BPCs and BPs (GSE17951) |
Senstivity | NA |
Specificity | NA |
AUC | Training: 0.836; Validation: 0.897 |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | quantitative real time polymerase chain reactions (qRT-PCR) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | NACA, CCNB1 |